What’s Better for Weight Loss: Wegovy or Ozempic?

Last reviewed: July 9, 2026

Last updated: July 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Both Wegovy and Ozempic contain the same active ingredient—semaglutide—yet they are not interchangeable. Wegovy is FDA-approved specifically for weight loss, while Ozempic is approved for type 2 diabetes management. Understanding the differences between these two medications, along with more affordable options, can help you make an informed choice about your treatment path.

The Core Difference Between Wegovy and Ozempic

Wegovy and Ozempic both work by activating GLP-1 receptors in the brain and digestive system, but they were developed and approved for different medical conditions. Wegovy received FDA approval in 2021 as a weight-loss medication and uses higher maximum doses than Ozempic. Ozempic was approved for type 2 diabetes in 2017 and maintains lower standard dose ranges. Although doctors may prescribe Ozempic off-label for weight loss, Wegovy remains the FDA-approved choice specifically designed for obesity treatment.

The dosing schedules also reflect their different purposes. Wegovy starts at 0.25 mg weekly and may increase to 2.4 mg over 16 weeks of treatment. Ozempic typically maxes out at 1 mg weekly for diabetes control. Many patients seeking weight loss have found Ozempic helpful, but this use falls outside its original indication. PlexusDx offers compounded semaglutide injection that eliminates the need to choose between brand-name medications, giving patients flexibility in dosing and significant cost savings.

Why Wegovy Costs More Than Ozempic

Wegovy's price tag—often $1,300 to $1,500 per month—reflects its exclusive FDA approval for weight loss and heavy marketing to the general public. Ozempic, marketed primarily to diabetes patients, typically costs $900 to $1,200 monthly and may be covered by some insurance plans when prescribed for diabetes. Neither medication is usually covered by insurance when prescribed off-label for weight loss alone. Most patients pay out of pocket for both medications, and copays or cash prices can become prohibitively expensive over months of treatment.

Compounded semaglutide injection from licensed 503A pharmacies offers a medically equivalent alternative without the premium brand-name markup. PlexusDx sources compounded semaglutide from licensed 503A compounding pharmacies and prices it starting at $189 per month, a fraction of brand-name Wegovy or Ozempic. Patients maintain the same clinical mechanism and efficacy while avoiding the financial burden that prevents many people from accessing GLP-1 therapy. No insurance is required, and the medication is HSA/FSA eligible, making it accessible to more patients seeking sustainable weight loss.

Clinical Effectiveness: What the Evidence Shows

Wegovy's clinical trial data demonstrates significant weight loss across multiple studies. In the STEP 1 trial, participants taking Wegovy 2.4 mg achieved average weight loss of 15% of their body weight over 68 weeks. Ozempic, when studied specifically for weight loss in off-label use, produced comparable results in many patients, though it was not formally tested in large weight-loss trials. Both medications work through identical pharmacology—activating GLP-1 receptors to increase satiety and reduce hunger signals.

The PlexusDx Precision Peptide Genetic Test analyzes GLP1R, GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Side Effects and Safety Profile

Wegovy and Ozempic share the same active ingredient, so their side effect profiles are virtually identical. Common side effects include nausea, vomiting, constipation, and diarrhea, particularly during dose escalation. Rare but serious side effects include pancreatitis and gallbladder issues. Most side effects diminish as the body adjusts over weeks to months. Both medications carry a black-box warning regarding medullary thyroid carcinoma risk in animal studies, though this has not been documented in human trials. Patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 should not use either medication.

Compounded semaglutide injections maintain the same safety profile as brand-name products because the active ingredient is identical. PlexusDx partners exclusively with licensed 503A compounding pharmacies, which follow strict quality and sterility standards enforced by the FDA. Patients should report any unusual symptoms to their healthcare provider immediately. The Precision Peptide Genetic Test from PlexusDx can help identify individuals with genetic predispositions that may influence medication tolerance or metabolic response, allowing for more tailored treatment plans and closer monitoring when indicated.

How PlexusDx Compounded Semaglutide Compares

PlexusDx offers compounded semaglutide injection starting at $189/mo (or $149/mo on the 6-month plan) through licensed 503A compounding pharmacies—delivering the same active pharmaceutical ingredient as Wegovy or Ozempic at a fraction of the brand-name cost. Patients receive personalized treatment without membership fees, insurance requirements, or surprise price increases based on dose escalation. The medication is available in all 50 states and is HSA/FSA eligible, making it financially accessible to a broader population seeking evidence-based weight loss treatment.

The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month) analyzes GLP1R (rs6923761), GIPR (rs1800437), FTO (rs9939609), and MC4R (rs17782313) — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to semaglutide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $189/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is Ozempic the same as Wegovy?

Both contain the same active ingredient—semaglutide—but Wegovy is FDA-approved for weight loss while Ozempic is approved for type 2 diabetes. Wegovy uses higher maximum doses and costs more due to its exclusive weight-loss indication. PlexusDx compounded semaglutide offers the same active ingredient at a lower price.

How much weight can I expect to lose with semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GLP1R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Why is PlexusDx semaglutide so much cheaper than Wegovy?

PlexusDx sources compounded semaglutide from licensed 503A compounding pharmacies, avoiding brand-name markup and direct-to-consumer marketing costs. Pricing starts at $189/month with no insurance required. Your dose may go up, but your price never changes—no per-dose ladder increases.

Are there serious side effects I should know about?

Common side effects include nausea, vomiting, and constipation during dose escalation; these usually resolve within weeks. Rare serious risks include pancreatitis and gallbladder inflammation. Both Wegovy and compounded semaglutide carry identical safety profiles. Always report unusual symptoms to your provider immediately.

How does the Precision Peptide Genetic Test help me?

No — the Precision Peptide Genetic Test does not predict your response to semaglutide or any specific medication. It analyzes pathway-level variants (GLP1R, GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Wegovy For Weight Loss 2
• Ozempic For Weight Loss 2
• Average Weight Loss On Ozempic
• Wegovy Weight Loss Pills

Pricing and availability current as of July 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.